Portada›Martes 30 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, martes 30 de septiembre de 2025

Los 40 documentos que 31 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← lunes 29 de septiembre de 2025 · miércoles 1 de octubre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. ACOGAlpha Cognition Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …the process of abandonment. S-3 NASDAQ Listing and Reverse Stock Split On November 12, 2024, our common shares began trading on the Nasdaq Capital Market under the symbol “ACOG”. On November 5, 2024, we completed a reverse stock split of our common shares with a stock split ratio of 1-for-25 (“Reverse Stock Split”). The Reverse Stock Split is intended to allow us to meet the minimum share price requirement of the Nasdaq Capital Market…
2. ARTLARTELO BIOSCIENCES, INC.424B5Nueva emisión de acciones con precioEDGAR
3. ARTLARTELO BIOSCIENCES, INC.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …of one of our product candidates. We expect to continue to fund our operations primarily through utilization of our current financial resources and additional raises of capital. These conditions raise substantial doubt about our ability to continue as a going concern. We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised substantial doubt about our ability to continue…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. S-3 Table of contents Recent Developments On July 18, 2025, we entered into an At-The-Market Offering Agreement (the “Sales Agreement”) with R. F. Lafferty & Co., Inc. (“Lafferty”) under which we may offer and sell up to $6.5 million of shares of our common stock from time to time through an “at the market…
4. BIAFbioAffinity Technologies, Inc.424B4Nueva emisión de acciones con precioEDGAR
5. ENTAENANTA PHARMACEUTICALS INC424B5Nueva emisión de acciones con precioEDGAR
6. GOVXGeoVax Labs, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …and may not remain in business. We have received a going concern opinion from our auditors. We have received a "going concern" opinion from our independent registered public accounting firm, reflecting substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability…
7. MDWDMediWound Ltd.424B5Nueva emisión de acciones con precioEDGAR
8. OCULOCULAR THERAPEUTIX, INC424B5Nueva emisión de acciones con precioEDGAR

   424B5 1 tm2526874-3_424b5.htm 424B5 ÍNDICE Presentado conforme a la Regla 424(b)(5) Número de registro 333-290597 SUPLEMENTO DE PROSPECTO (Al Prospecto de fecha 30 de septiembre de 2025) 37.909.018 acciones ordinarias Ofrecemos 37.909.018 acciones de nuestra acción ordinaria… Sigue en la ficha

   Original en inglés · traducción automática

   424B5 1 tm2526874-3_424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5)​ Registration No. 333-290597​ P R O S P E C T U S S U P P L E M E N T (To Prospectus dated September 30, 2025) 37,909,018 Shares Common Stock ​ We are offering 37,909,018 shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “OCUL.” On September 29, 2025, the closing price of our common stock, as reported on The Nasdaq Global Market, was $12.53 per share. Investing in our common stock involves significant risk. See “Risk Factors” on page S-3 of this prospectus supplement and the documents incorporated by reference into this prospectus supplement. ​ ​ ​ ​ Per Share ​ ​ Total ​ Offering price ​ ​ ​ $ 12.53 ​ ​ ​ ​ $ 474,999,996 ​ ​ Underwriting discounts and commissions(1) ​ ​ ​ $ 0.7518 ​ ​ ​ ​ $ 28,500,000 ​ ​ Proceeds, before

   Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

9. REVBREVELATION BIOSCIENCES, INC.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …have been audited by Baker Tilly US, LLP, an independent registered public accounting firm, as stated in their report thereon (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), incorporated herein by reference, and have been incorporated in this prospectus and registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and…
10. REVBREVELATION BIOSCIENCES, INC.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …have been audited by Baker Tilly US, LLP, an independent registered public accounting firm, as stated in their report thereon (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), incorporated herein by reference, and have been incorporated in this prospectus and registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and…
11. ALLRAllarity Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR

    El folleto de Allarity Therapeutics cubre la reventa por un accionista vendedor de hasta 1.562.500 acciones ordinarias.

    Original en inglés · traducción automática

    1,562,500 Shares of Common Stock Offered by the Selling Stockholder This prospectus relates to the resale, from time to time, by the selling stockholder identified herein, of up to 1,562,500 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Allarity Therapeutics, Inc.

    Traducción automática (claude-sonnet-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

12. CRMDCorMedix Inc.S-3Capacidad de emisión registradaEDGAR
13. GRMLGreenland Mines Ltd424B3Prospecto suplementario o de reventaEDGAR
14. LFCRLIFECORE BIOMEDICAL, INC. \DE\424B3Prospecto suplementario o de reventaEDGAR
15. OCULOCULAR THERAPEUTIX, INCS-3ASRCapacidad de emisión registradaEDGAR
16. STTKShattuck Labs, Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

1. ALZNAlzamend Neuro, Inc.SC 13D/ACambio en participación significativaEDGAR
2. MBXMBX Biosciences, Inc.SC 13D/ACambio en participación significativaEDGAR
3. MBXMBX Biosciences, Inc.SC 13D/ACambio en participación significativaEDGAR
4. MBXMBX Biosciences, Inc.SC 13D/ACambio en participación significativaEDGAR
5. NAMSNewAmsterdam Pharma Co N.V.SC 13D/ACambio en participación significativaEDGAR
6. PEPGPepGen Inc.SC 13D/ACambio en participación significativaEDGAR
7. PRQRProQR Therapeutics N.V.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. BIAFbioAffinity Technologies, Inc.8-KNuevo acuerdo materialEDGAR
   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …compliance with the Continued Listing Equity Requirement. On July 14, 2025, the Company submitted its plan to regain compliance with the Continued Listing Equity Requirement. On August 7, 2025, the Company received written notice from the Staff that it had not regained compliance with the Minimum Bid Price Requirement by August 6, 2025, and was not eligible for a second 180-day compliance period as the Company did not comply with the minimum stockholders’ equity requirement for initial listing on the Nasdaq…
2. GOVXGeoVax Labs, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
3. INMBInmune Bio, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoEl ensayo NO alcanzó su objetivo principaltexto original ▸

   …manuscript provides a comprehensive analysis of the trial, which evaluated the safety and efficacy of XPro™ in patients with early Alzheimer’s disease and biological signs of inflammation. While the study did not meet its primary endpoint in the overall population, the findings reveal a promising signal in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden, defined by two or more biomarkers of…
4. MIRAMIRA PHARMACEUTICALS, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
5. BRNSBarinthus Biotherapeutics plc.8-KNuevo acuerdo materialEDGAR
6. EDSAEdesa Biotech, Inc.8-KNuevo acuerdo materialEDGAR
7. ICCCIMMUCELL CORP /DE/8-KNuevo acuerdo materialEDGAR
8. IRDOpus Genetics, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoDesignación de terapia avanzada (RMAT)texto original ▸

   …remains well tolerated with no ocular serious adverse events or dose-limiting toxicities. The adult cohort showed durable improvements in cone sensitivity and visual function out to 18 months. OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. About Leber Congenital Amaurosis (LCA) and LCA5 Leber congenital amaurosis (LCA) is a group of inherited retinal diseases characterized by severe impaired vision or blindness…
9. LENZLENZ Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
10. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
11. OCULOCULAR THERAPEUTIX, INC8-KOtros hechos relevantesEDGAR
12. OCULOCULAR THERAPEUTIX, INC8-KNuevo acuerdo materialEDGAR

    Ocular Therapeutix anunció la fijación del precio de una oferta suscrita de 37.909.018 acciones comunes a 12,53 dólares por acción, con ingresos brutos de aproximadamente 475,0 millones de dólares.

    Original en inglés · traducción automática

    today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

    Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

13. PCVXVaxcyte, Inc.8-KNuevo acuerdo materialEDGAR
14. PMNProMIS Neurosciences Inc.8-KCambio en el consejo o la direcciónEDGAR
15. SABSSAB Biotherapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
16. TNXPTonix Pharmaceuticals Holding Corp.8-KOtros hechos relevantesEDGAR
17. ZURAZura Bio Ltd8-KCambio en el consejo o la direcciónEDGAR

← lunes 29 de septiembre de 2025 · miércoles 1 de octubre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.